• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 17, 2014

View Archived Issues

Bench Press: BioWorld looks at translational medicine

An investigative committee at the Japanese Riken Institute has said it found two instances of “inappropriate handling” of data in recent high-profile papers on a new way of generating cells with stem cell-like characteristics. Read More

Appointments and advancements

Amicus Therapeutics Inc., of Cranbury, N.J., appointed Jay A. Barth chief medical officer, and Bradley L. Campbell, previously chief business officer, has been named chief operating officer. Read More

Pharma: other news to note

Merck & Co. Inc., of Whitehouse Station, N.J., said the FDA approved Noxafil (posaconazole) injection (18 mg/ mL), a new formulation of Noxafil for intravenous use. Merck’s antifungal agent is also marketed as Noxafil (100 mg) delayed-release tablets and Noxafil (40 mg/mL) oral suspension. Read More

Stock movers

Read More

Clinic roundup

Achillion Pharmaceuticals Inc., of New Haven, Conn., said presentations at the Asian Pacific Association for the Study of the Liver in Brisbane, Australia, included updated phase II results evaluating a 150-mg loading dose following by 50 mg once daily of ACH-3102, a second-generation NS5A inhibitor, in combination with either once-daily 200 mg or 400 mg of sovaprevir and twice-daily ribavirin in hepatitis C virus (HCV) patients. Read More

Other news to note

Intrexon Corp., of San Carlos, Calif., said it acquired laboratory operations in Budapest, Hungary, from Codexis Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries. Read More

Study shows antibiotic class can affect apoptosis

Researchers may have discovered why a certain antibiotic class can be highly toxic, and a pathway toward making it less so, while looking for something different altogether. Read More

Diversity in clinical trials gets push in national campaign

Despite the mandate in section 907 of the FDA Safety and Innovation Act of 2012 (FDASIA) that the FDA seek the inclusion of demographic “subgroups” in clinical trials, both the agency and drugmakers have struggled to improve participation rates among historically underrepresented populations, especially African Americans and Hispanics. Read More

Asia’s biopharmas eye biosimilars; manufacturing capabilities established

SINGAPORE – Biosimilars are generating more interest among Asian developers, which are rapidly moving into a space that is likely to see skyrocketing sales before the end of the decade. Read More

Ignyta firing up IPO: $44M for cancer bid with kinase inhibitors

Already trading weakly as a public entity thanks to its reverse merger in the fall of last year, Ignyta Inc. priced an initial public offering (IPO) of about 5.2 million shares at $9.15 each, for gross proceeds of about $48 million and a net haul of about $44.5 million. Read More

Glaxosmithkline and Theravance seek ‘Advair’ advantage; data bolster Anoro

News of additional positive data from three phase III trials for Anoro Ellipta (umeclidinium/vilanterol), the first FDA-approved combo long-acting beta2-adrenergic agonist (LABA)/long-acting muscarinic antagonist (LAMA), generated little buzz for Theravance Inc., though it adds further ammunition as partner Glaxosmithkline plc fights to maintain its hold on the respiratory disease market in the face of generic threats to its top-selling Advair/Seretide franchise. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe